1. Home
  2. REAX vs AKBA Comparison

REAX vs AKBA Comparison

Compare REAX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REAX
  • AKBA
  • Stock Information
  • Founded
  • REAX 2018
  • AKBA 2007
  • Country
  • REAX United States
  • AKBA United States
  • Employees
  • REAX N/A
  • AKBA N/A
  • Industry
  • REAX
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • REAX
  • AKBA Health Care
  • Exchange
  • REAX Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • REAX 872.2M
  • AKBA 958.6M
  • IPO Year
  • REAX N/A
  • AKBA 2014
  • Fundamental
  • Price
  • REAX $3.95
  • AKBA $3.68
  • Analyst Decision
  • REAX Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • REAX 2
  • AKBA 5
  • Target Price
  • REAX $6.00
  • AKBA $6.90
  • AVG Volume (30 Days)
  • REAX 918.5K
  • AKBA 6.1M
  • Earning Date
  • REAX 08-06-2025
  • AKBA 08-07-2025
  • Dividend Yield
  • REAX N/A
  • AKBA N/A
  • EPS Growth
  • REAX N/A
  • AKBA N/A
  • EPS
  • REAX N/A
  • AKBA N/A
  • Revenue
  • REAX $1,417,877,000.00
  • AKBA $184,909,000.00
  • Revenue This Year
  • REAX $43.20
  • AKBA $26.88
  • Revenue Next Year
  • REAX $15.30
  • AKBA $44.34
  • P/E Ratio
  • REAX N/A
  • AKBA N/A
  • Revenue Growth
  • REAX 81.30
  • AKBA N/A
  • 52 Week Low
  • REAX $3.55
  • AKBA $0.80
  • 52 Week High
  • REAX $6.75
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • REAX 36.85
  • AKBA 64.49
  • Support Level
  • REAX $3.86
  • AKBA $3.46
  • Resistance Level
  • REAX $4.06
  • AKBA $3.98
  • Average True Range (ATR)
  • REAX 0.17
  • AKBA 0.25
  • MACD
  • REAX -0.02
  • AKBA -0.04
  • Stochastic Oscillator
  • REAX 24.41
  • AKBA 64.20

About REAX The Real Brokerage Inc.

The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: